SIGN UP

Stay informed of the latest progress in canine health research.

DONATE

We need your support to fund research that helps dogs live longer, healthier lives.

 

Donate Today

Immunotherapy for Canine Meningioma

09/12/2011

By G. Elizabeth Pluhar, D.V.M., Ph.D., Dip ACVS1, John R. Ohlfest, Ph.D.2, and Matthew A. Hunt, M.D.
1Department of Veterinary Clinical Sciences, College of Veterinary Medicine; 2Department of Pediatrics, School of Medicine; 3Department of Neurosurgery, School of Medicine

Meningiomas are the most common brain tumor in dogs. Surgical removal is the mainstay of treatment, and most of these tumors are managed with local therapy. Historically, the survival time of dogs with meningiomas treated with surgery alone has been four and one-half to seven months. Systemic therapies so far have had limited effectiveness. However, based on preclinical data from our research program, we embarked on the development of anti-tumor vaccinations to treat dogs with spontaneous meningiomas after surgical removal.

Thirteen dogs have been treated with surgical removal of the tumor followed by a series of vaccinations made from the dog’s own tumor cells (called an “autologous tumor lysate” vaccine), along with one of two immune stimulators. The vaccines were injected into the skin on the back of the dog’s neck two weeks after surgery at suture removal. A total of six vaccinations were given at two-week intervals. All 13 dogs have completed the vaccination series.

Canine
A patient is prepared for the MRI at the University of Minnesota Veterinary Medical Center

Magnetic resonance imaging (MRI) of the brain was performed immediately after surgery to assess whether the tumor mass was completely removed, and 3, 6, and 12 months after surgery to check for tumor recurrence. Blood collected from each dog during the visits for the MRIs was analyzed for an immune response against the tumor. High-grade malignant tumors were found in two dogs, and low-grade tumors were found in the remaining 11 dogs.

A survival analysis comparing dogs treated with surgery and vaccines to dogs that had surgical removal alone demonstrated a significant survival improvement in the dogs receiving the vaccine therapy. To date, the mean survival time in dogs treated with surgery and vaccines is about one year, with many of the treated dogs still alive and tumor-free, compared to a survival time of approximately 200 days in dogs treated with surgery alone. We also have not seen severe toxicities or side effects in the vaccine-treated dogs. Immune testing demonstrated an antibody response as well as enhanced tumor cell killing by the treated dogs’ lymphocytes.

Our results indicate that immunotherapy using autologous tumor lysate and immune adjuvant after tumor removal elicits specific immune responses against residual tumor cells and increases survival over historical controls. Since this therapy appears to work so well in dogs with meningiomas, it may also be effective in humans with meningiomas that have failed to respond to the standard therapy or are at high risk of recurrence.

Although the pilot phase for this trial is complete and we are not currently recruiting dogs with meningiomas, we are waiting to hear whether two grant proposals to continue our work on dogs with meningiomas will be funded. Check the CVM Clinical Investigation Center website at www.cvm.umn.edu/cic/current/ braintumortrials for more information, applications to enroll dogs in clinical trials, or to make a contribution to support this research.

 

  • Printer Friendly

Listen to the Latest Podcast

An Interview with Susan Lilly, New CEO of the AKC Canine Health Foundation

12/18/2014

In this podcast we hear from Susan Lilly, the new CEO of the AKC Canine Health Foundation. A native of Michigan, Susan boasts a strong fundraising background. After holding development positions at Central Michigan University, she served as Director of Development at Michigan State University and, most recently, was Executive Director of the North Carolina State University Veterinary Health Foundation. In this podcast Susan discusses her passion for helping animals, her enthusiasm about being a part of CHF and its mission, and her desire to connect with you and the many supporters of CHF.

This podcast was made possible thanks to the generous support of the Kenneth A. Scott Charitable Trust, A KeyBank Trust.


Listen